Free Trial

Haleon (HLN) Stock Forecast & Price Target

Haleon logo
$11.01 +0.13 (+1.19%)
As of 05/20/2025 03:58 PM Eastern

Haleon - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
5
Buy
4

Based on 9 Wall Street analysts who have issued ratings for Haleon in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 5 have given a hold rating, 3 have given a buy rating, and 1 has given a strong buy rating for HLN.

Consensus Price Target

$11.25
2.18% Upside
According to the 9 analysts' twelve-month price targets for Haleon, the average price target is $11.25. The highest price target for HLN is $11.25, while the lowest price target for HLN is $11.25. The average price target represents a forecasted upside of 2.18% from the current price of $11.01.
Get the Latest News and Ratings for HLN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Haleon and its competitors.

Sign Up

HLN Analyst Ratings Over Time

TypeCurrent Forecast
5/21/24 to 5/21/25
1 Month Ago
4/21/24 to 4/21/25
3 Months Ago
2/21/24 to 2/20/25
1 Year Ago
5/22/23 to 5/21/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
1 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
Hold
5 Hold rating(s)
6 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$11.25$10.95$10.95N/A
Forecasted Upside2.18% Upside7.46% Upside10.77% UpsideN/A
Consensus Rating
Moderate Buy
Hold
Moderate Buy
Moderate Buy

HLN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HLN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Haleon Stock vs. The Competition

TypeHaleonMedical CompaniesS&P 500
Consensus Rating Score
2.56
2.81
2.54
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside2.18% Upside4,843.40% Upside13.03% Upside
News Sentiment Rating
Positive News

See Recent HLN News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/9/2025Morgan Stanley
3 of 5 stars
 UpgradeEqual Weight ➝ Overweight$11.25+6.38%
5/6/2025Barclays
3 of 5 stars
 Reiterated RatingOverweight ➝ Overweight
3/5/2025Hsbc Global Res
0 of 5 stars
J. Fialko
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
3/5/2025HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
3/3/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold ➝ Hold
1/8/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Elliott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
10/1/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Delmas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/6/2024Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Davies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
8/6/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
O. Nicolai
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
3/26/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy
8/8/2023Investec
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Hold
5/24/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:21 AM ET.


Should I Buy Haleon Stock? HLN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, May 16, 2025. Please send any questions or comments about these Haleon pros and cons to contact@marketbeat.com.

Haleon
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Haleon plc:

  • The company recently reported earnings per share (EPS) of $0.05, indicating a positive financial performance that may attract investors looking for growth.
  • Haleon plc has a strong return on equity of 14.76%, suggesting effective management and profitability, which can be appealing to potential investors.
  • The business achieved revenue of $3.54 billion during the quarter, surpassing analyst estimates, which reflects strong market demand for its consumer healthcare products.
  • Haleon plc has increased its dividend to $0.1166 per share, representing a yield of 1.6%. This increase from the previous dividend indicates a commitment to returning value to shareholders.
  • The current stock price is around $11.25, which is considered reasonable given the company's recent performance and growth potential, making it an attractive entry point for investors.

Haleon
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Haleon plc for these reasons:

  • Despite the positive earnings report, the overall market sentiment may be cautious, as some analysts have maintained a "hold" rating on the stock, indicating uncertainty about future performance.
  • The dividend payout ratio is currently at 58.97%, which, while sustainable, may limit the company's ability to reinvest in growth opportunities.
  • Institutional investors and hedge funds own only 6.67% of the company's stock, suggesting a lack of confidence from larger investors, which could impact stock performance.
  • Recent analyst upgrades have been mixed, with some firms downgrading their ratings, which may create volatility and uncertainty for potential investors.
  • Haleon plc operates in a competitive market for consumer healthcare products, which could pressure margins and affect long-term profitability.

HLN Forecast - Frequently Asked Questions

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Haleon is $11.25, with a high forecast of $11.25 and a low forecast of $11.25.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haleon in the last year. There are currently 5 hold ratings, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HLN shares.

According to analysts, Haleon's stock has a predicted upside of 2.18% based on their 12-month stock forecasts.

Over the previous 90 days, Haleon's stock had 1 upgrade and 1 downgrade by analysts.

Haleon has been rated by research analysts at Barclays, Deutsche Bank Aktiengesellschaft, Hsbc Global Res, HSBC, and Morgan Stanley in the past 90 days.

Analysts like Haleon less than other "medical" companies. The consensus rating score for Haleon is 2.56 while the average consensus rating score for "medical" companies is 2.81. Learn more on how HLN compares to other companies.


This page (NYSE:HLN) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners